Objective: The aim of this study was to determine the characteristics of the testicular cancer that were managed in Soetomo Hospital. Materials & Methods: This was a retrospective descriptive study. We reviewed the medical records of patient with testicular tumor admitted in Soetomo Teaching Hospital Surabaya, from January 2008 until December 2013. The data regarding demographic characteristics, clinical presentation, grading and staging based on pathological examination result, and the management of the cancer. Data was presented in tabular and narrative in order to know the number and percentage of testicular cancer in Surabaya. Results: There were 46 patients with testicular cancer with mean age of 27.1 ± 7.9 years. Peak incidence was 15–35 years old (54%). Testicular mass was the most frequent clinical presentation in 42 patients (91%), abdominal mass and other complaints in 4 patients (9%). Most of the patients live outside Surabaya in 34 patients (72%). Location of the tumor was more frequently in scrotum, which occured in 42 patients (91%). A total of 4 patients (9%) were found to have a history of UDT. Based on the TNM staging, patients with stage pT3 were as many as 20 patients (43%), pT4 11 patients (24%), pT2 7 patients (15%) and pT1 4 patients (9%). In regional lymph nodes staging (N) N3 were as many as 26 patients (57%), N0 9 patients (20%), N2 5 patients (11%) and N1 2 patients (4%). Metastase staging (M) M0 was found in 27 patients (58%) and M1 tumor was found 42%. The major pathological finding was seminoma in 37 patients (80%), Yolk sac tumor in 4 patients (9%), Embryonal Ca in 1 patient (2%), Teratoma in 1 patient (2%) and mixed germ cell tumor in 3 patients (7%). The most widely theraphy was underwent orchidectomy followed by PEB chemotheraphy in 29 patients (64%), 3 patients (6%) underwent EBRT and PEB chemotheraphy, 5 patients (11%) underwent PEB chemotheraphy, There were 9 patients (19%) underwent orchidectomy alone. Group of seminoma tumor show normal limit of tumor marker α-FP and β-HCG and increased in non seminoma. Conclusion: Testicular cancer mostly appears in younger males. Most of testicular cancer was seminoma, diagnosed in advanced stage with metastase 42% of the patient. Most of the patients received orchidectomy followed by PEB chemotheraphy.
Germ cell tumor, testicular cancer, radical orchidectomy
Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev. May 2010; 19(5): 1151-9.
Rustom P. Manecksha, John M. Fitzpatrick. Epidemiology of testicular cancer. BJU International; 2009. p. 1333.
Andrew Cramer, Mike B Siroky. Neoplasma of the genitourinary tract. Handbook of Urology, 3rd ed. Lippincott Williams & Wilkins. 2004; Chap 15: 249–99.
American Cancer Society. Cancer facts & figures 2015. Available at http: firstname.lastname@example.org. Accessed February 16, 2015.
Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H. Second cancers among 40,576 testicular cancer patients focus on long-term survivors. J Natl Cancer Inst. 2005 Sep 21; 97(18): 1354-65.
McGlynn KA, Devesa SS, Graubard BI, Castle PE. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol. 2005 Aug 20; 23(24): 5757-61.
John Reynard, Simon Brewster, Suzanna Biers. Testicular cancer. Oxford Handbook of Urology, 2nd ed. Oxford University Press. 2009; Chap 7: 357–69.
Jerome P Richie, Graeme S Steele. Neoplasma of the Testis. Campbell – Walsh Urology, 10th ed. Elsevier; 2012: Chap 31.
Jane Houldsworth, George J Bose, RSK Chaganti. Genetics and biology of adult male germ cell tumor. Urologycal Cancer. Springer. 2005; Chap 19: 221–29.
Motzer RJ, Sheinfeld J, Mazumdar M. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol. Nov 1995; 13(11): 2700-4.
International Germ Cell Cancer. International germ cell consensus classification a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. Feb 1997; 15(2): 594-603.